{"hands_on_practices": [{"introduction": "The clinical presentation of IgA nephropathy can overlap significantly with other glomerular diseases, making differential diagnosis a critical first step. This exercise challenges you to apply fundamental principles of immunology and pathophysiology, particularly the timing of the immune response, to distinguish IgA nephropathy from post-streptococcal glomerulonephritis. Mastering this skill is essential for forming an accurate initial assessment and guiding the subsequent diagnostic workup. [@problem_id:5184311]", "problem": "A pediatrician evaluates two unrelated children presenting with gross, cola-colored urine. You are asked to assign the most likely diagnoses using only first principles of immune response kinetics and basic renal pathophysiology, and to justify your choice.\n\nFundamental base you may assume: the primary adaptive immune response to a new protein antigen requires antigen capture and presentation, T-cell help, clonal expansion, and class-switching, leading to a characteristic lag phase of approximately $7$ to $14$ days before peak antibody production. In contrast, mucosal immune responses dominated by Immunoglobulin A (IgA) can be rapidly upregulated during an ongoing mucosal infection, especially in previously primed hosts, with clinical sequelae manifesting within $<72$ hours. Complement consumption differs by pathway: alternative pathway activation commonly depresses serum complement component 3 (C3) with relatively preserved complement component 4 (C4), whereas classical pathway activation often reduces both.\n\nCase $1$: An $8$-year-old boy develops facial puffiness and cola-colored urine $10$ days after a sore throat that resolved without antibiotics. Vital signs show blood pressure at the $95$th percentile for age. Urinalysis reveals dysmorphic red blood cells (red blood cell casts present) with a urine protein-to-creatinine ratio of $0.8$ mg/mg. Serum creatinine is $0.9$ mg/dL. Serum C3 is $45$ mg/dL (reference $90$–$180$ mg/dL), C4 is $normal$, and Antistreptolysin O (ASO) titer is elevated at $600$ Todd units.\n\nCase $2$: A $13$-year-old previously healthy boy notes cola-colored urine that begins within $24$ hours of onset of a febrile sore throat; he recalls similar episodes during prior colds. Vital signs show normal blood pressure. Urinalysis reveals dysmorphic red blood cells (red blood cell casts present) with a urine protein-to-creatinine ratio of $0.2$ mg/mg. Serum creatinine is $0.8$ mg/dL. Serum IgA is mildly elevated for age. Serum C3 and C4 are within reference ranges. There is no rash, arthritis, or abdominal pain.\n\nBased on the latent period kinetics between mucosal infection and the onset of hematuria, as well as the complement patterns and degree of proteinuria, which pairing of diagnoses is most likely?\n\nA. Case $1$: Acute Post-Streptococcal Glomerulonephritis (APSGN); Case $2$: Immunoglobulin A Nephropathy (IgAN)\n\nB. Case $1$: Immunoglobulin A Nephropathy (IgAN); Case $2$: Acute Post-Streptococcal Glomerulonephritis (APSGN)\n\nC. Case $1$: Membranoproliferative Glomerulonephritis; Case $2$: Minimal Change Disease\n\nD. Case $1$: Hemolytic Uremic Syndrome; Case $2$: Henoch–Schönlein Purpura (IgA vasculitis) renal involvement", "solution": "The task is to diagnose two cases of pediatric glomerulonephritis by applying the provided first principles of immunology and pathophysiology.\n\n**Analysis of Case $1$**\n1.  **Temporal Latency:** The patient develops symptoms $10$ days after a sore throat. This latency falls squarely within the $7$ to $14$ day lag phase stated to be characteristic of a primary adaptive immune response. This points towards a post-infectious etiology.\n2.  **Evidence of Infection:** The history of a preceding sore throat and the significantly elevated Antistreptolysin O (ASO) titer of $600$ Todd units provide strong evidence of a recent Group A Streptococcus infection.\n3.  **Clinical Features:** The presentation includes cola-colored urine (gross hematuria), facial puffiness (edema), and hypertension (BP at $95$th percentile). The urinalysis finding of dysmorphic RBCs and RBC casts confirms a glomerular origin of the hematuria, classifying this as an acute nephritic syndrome. The proteinuria is in the sub-nephrotic range (urine protein-to-creatinine ratio of $0.8$ mg/mg).\n4.  **Complement Pattern:** The serum C3 is low ($45$ mg/dL) while the C4 is normal. According to the provided principles, this pattern is characteristic of alternative pathway activation.\n5.  **Synthesis for Case $1$:** The combination of a nephritic syndrome with a latent period of $10$ days following a confirmed streptococcal infection, coupled with low serum C3 and normal C4, is the quintessential presentation of Acute Post-Streptococcal Glomerulonephritis (APSGN).\n\n**Analysis of Case $2$**\n1.  **Temporal Latency:** The patient develops gross hematuria within $24$ hours of the onset of a febrile sore throat. This extremely short latency period is described in the problem as manifesting within $<72$ hours, characteristic of a rapidly upregulated mucosal IgA response. This is known as \"synpharyngitic\" hematuria. The history of similar recurrent episodes reinforces this pattern.\n2.  **Clinical Features:** The patient presents with isolated gross hematuria of glomerular origin (dysmorphic RBCs, RBC casts). Importantly, blood pressure is normal, proteinuria is minimal (urine protein-to-creatinine ratio of $0.2$ mg/mg), and there are no systemic symptoms (rash, arthritis, abdominal pain).\n3.  **Complement Pattern:** Serum C3 and C4 levels are both normal. This rules out complement-consuming processes like APSGN.\n4.  **Immunologic Clue:** The serum IgA is mildly elevated.\n5.  **Synthesis for Case $2$:** The constellation of recurrent, synpharyngitic gross hematuria linked to mucosal infections, normal complement levels, and elevated serum IgA is the classic presentation of Immunoglobulin A Nephropathy (IgAN). The absence of systemic symptoms distinguishes it from the systemic form, IgA vasculitis (Henoch-Schönlein Purpura).\n\n**Conclusion of Derivation**\nBased on the direct application of the provided principles to the case data:\n*   Case $1$ is most likely Acute Post-Streptococcal Glomerulonephritis (APSGN).\n*   Case $2$ is most likely Immunoglobulin A Nephropathy (IgAN).\n\n**Option-by-Option Analysis**\n\n*   **A. Case $1$: Acute Post-Streptococcal Glomerulonephritis (APSGN); Case $2$: Immunoglobulin A Nephropathy (IgAN)**\n    This option perfectly aligns with the derivation. Case $1$ exhibits the post-infectious latency and low C3 of APSGN. Case $2$ exhibits the synpharyngitic latency and normal C3 of IgAN.\n    **Verdict: Correct.**\n\n*   **B. Case $1$: Immunoglobulin A Nephropathy (IgAN); Case $2$: Acute Post-Streptococcal Glomerulonephritis (APSGN)**\n    This option incorrectly reverses the diagnoses. Case $1$ has a $10$-day latency and low C3, which are inconsistent with IgAN. Case $2$ has a $24$-hour latency and normal C3, which are inconsistent with APSGN.\n    **Verdict: Incorrect.**\n\n*   **C. Case $1$: Membranoproliferative Glomerulonephritis; Case $2$: Minimal Change Disease**\n    For Case $1$, while some forms of Membranoproliferative Glomerulonephritis (MPGN) cause low C3, the acute onset following a confirmed streptococcal infection makes APSGN a far more probable diagnosis. For Case $2$, Minimal Change Disease (MCD) is a cause of nephrotic syndrome (heavy proteinuria) and typically does not present with a prominent nephritic picture of gross hematuria and RBC casts. The patient's proteinuria is minimal.\n    **Verdict: Incorrect.**\n\n*   **D. Case $1$: Hemolytic Uremic Syndrome; Case $2$: Henoch–Schönlein Purpura (IgA vasculitis) renal involvement**\n    For Case $1$, Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy characterized by a triad of hemolytic anemia, thrombocytopenia, and acute kidney injury. The patient in Case $1$ does not have these features. For Case $2$, while the renal lesion of Henoch-Schönlein Purpura (HSP) is IgA nephropathy, HSP is a systemic vasculitis. The problem explicitly states the absence of the characteristic extra-renal features (rash, arthritis, abdominal pain), making the diagnosis of renal-limited IgAN more precise.\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5184311"}, {"introduction": "Confirming a diagnosis of IgA nephropathy requires a kidney biopsy, but deciding which patients should undergo this invasive procedure is a complex clinical judgment. This practice places you in the role of the clinician, tasked with performing a risk-benefit analysis based on key prognostic indicators. You will learn to weigh the diagnostic and prognostic information gained from a biopsy against its inherent risks to make an informed decision. [@problem_id:4389303]", "problem": "A clinician is considering whether to perform a percutaneous kidney biopsy in patients with suspected Immunoglobulin A (IgA) nephropathy (Berger disease), defined clinically by episodes of gross hematuria after upper respiratory infections, persistent microscopic hematuria, and variable proteinuria. Renal biopsy confirms the diagnosis by demonstrating mesangial deposition of IgA on immunofluorescence and guides risk stratification and therapy decisions. However, biopsy carries complication risks. You are asked to define clinically sound thresholds for recommending biopsy that balance expected diagnostic yield against procedural risk.\n\nUse the following well-tested facts and definitions as the fundamental base for your reasoning:\n\n- IgA nephropathy is a primary glomerulonephritis diagnosed definitively by renal biopsy with identification of mesangial Immunoglobulin A (IgA) deposition. Immunofluorescence has high sensitivity for mesangial IgA deposition in true IgA nephropathy (approximately $0.95$).\n- Percutaneous renal biopsy has a major bleeding complication rate on the order of $0.5\\%$ to $1.0\\%$, minor complication rate around $3\\%$ to $5\\%$, and procedure-related mortality less than $0.1\\%$ in contemporary practice.\n- Estimated Glomerular Filtration Rate (eGFR) reflects kidney function; a sustained decline indicates progressive disease. Proteinuria magnitude correlates with risk of progression in IgA nephropathy; persistent proteinuria $\\geq 1$ g/day is a prognostic threshold frequently used to trigger intensification of management.\n- Pretest probability (clinical likelihood before biopsy) and test characteristics determine diagnostic yield; performing biopsy in higher pretest probability states increases the chance that the biopsy materially changes management decisions.\n\nConsider three common clinical phenotypes encountered in suspected IgA nephropathy:\n\n- Phenotype X: isolated microscopic hematuria, urine protein $< 0.3$ g/day over $3$ consecutive months, stable serum creatinine and estimated Glomerular Filtration Rate (eGFR) $\\geq 90~\\text{mL/min/1.73~m}^2$, normal blood pressure. Pretest probability of IgA nephropathy $\\approx 0.40$.\n- Phenotype Y: persistent microscopic hematuria, urine protein averaging $0.5$ to $1.0$ g/day over $3$ months despite optimized renin-angiotensin system blockade, new-onset hypertension ($\\geq 140/90$ mmHg) or a reproducible decline in eGFR of $> 10~\\text{mL/min/1.73~m}^2$ over $6$ months. Pretest probability of IgA nephropathy $\\approx 0.70$.\n- Phenotype Z: macroscopic hematuria with acute kidney injury (rise in serum creatinine consistent with eGFR decrease $> 20~\\text{mL/min/1.73~m}^2$ from baseline) or nephrotic-range proteinuria $\\geq 3.5$ g/day. Pretest probability of IgA nephropathy $\\approx 0.85$.\n\nAssume immunofluorescence sensitivity for detecting mesangial IgA in true disease is $0.95$ and that non-IgA glomerulopathies comprise the remainder in these phenotypes. Use risk-benefit analysis grounded in the above facts to justify which thresholds for biopsy are appropriate.\n\nWhich option most appropriately defines clinical thresholds for performing kidney biopsy in suspected IgA nephropathy and justifies them against procedural risks and expected diagnostic yield?\n\nA. Perform biopsy in all suspected cases (any hematuria), because confirmatory histology always outweighs the small risk; do not consider proteinuria magnitude or eGFR trend.\n\nB. Recommend biopsy when proteinuria is persistent and $\\geq 1$ g/day and/or there is a sustained decline in eGFR of $> 10~\\text{mL/min/1.73~m}^2$ over $6$ months, or when macroscopic hematuria is accompanied by acute kidney injury; defer biopsy in isolated microscopic hematuria with proteinuria $< 0.5$ g/day and stable eGFR. This balances higher diagnostic yield in Phenotypes Y and Z against the $0.5$–$1.0\\%$ major complication risk, while avoiding low-yield biopsy in Phenotype X.\n\nC. Only biopsy if nephrotic-range proteinuria $\\geq 3.5$ g/day or hypertension is present; do not biopsy for declining eGFR unless serum creatinine has doubled from baseline.\n\nD. Defer biopsy until eGFR has fallen below $60~\\text{mL/min/1.73~m}^2$ or serum creatinine has increased by $> 100\\%$, because risks otherwise outweigh benefits; isolated microscopic hematuria and subnephrotic proteinuria never warrant biopsy.\n\nE. Biopsy whenever red blood cell (RBC) casts are detected on urinalysis, regardless of proteinuria or kidney function, because RBC casts make IgA nephropathy highly likely and justify the procedural risk.", "solution": "The core of the task is to balance the benefit of a definitive diagnosis against the risks of a percutaneous renal biopsy. The benefit is not merely diagnostic confirmation but the potential to alter management, specifically to initiate therapies that can prevent the progression to end-stage kidney disease. The risks, while modest, are non-zero, with a major complication rate of $0.5\\%$ to $1.0\\%$. A biopsy is therefore justified when the expected information is likely to lead to a change in management that outweighs this risk.\n\nLet's analyze the three phenotypes based on this principle:\n\n1.  **Phenotype X**: Isolated microscopic hematuria, proteinuria $< 0.3$ g/day, and stable eGFR $\\geq 90~\\text{mL/min/1.73~m}^2$. These patients have a very low risk of disease progression. Even if a biopsy confirmed IgA nephropathy (pretest probability is $0.40$), current clinical guidelines would recommend conservative management (e.g., blood pressure control) and monitoring, not immunosuppression. The biopsy result would not change management. Therefore, the benefit is low (diagnostic labeling without therapeutic consequence) and does not justify the procedural risk. Biopsy should be deferred.\n\n2.  **Phenotype Y**: Persistent proteinuria of $0.5$ to $1.0$ g/day, new-onset hypertension, or a declining eGFR ($> 10~\\text{mL/min/1.73~m}^2$ over $6$ months). These are all established risk factors for progression in IgA nephropathy. A key therapeutic decision point is reached when proteinuria is persistently $\\geq 1$ g/day despite optimized supportive care, as this is often an indication for considering corticosteroid therapy or other immunosuppression. Patients in this category are approaching or have reached this threshold. A definitive diagnosis is critical to justify initiating such therapies, which have their own significant side effects. The biopsy provides this diagnosis and also crucial prognostic details (e.g., from the MEST-C score) that further refine treatment decisions. The pretest probability is high ($0.70$), increasing the likelihood that the biopsy will be informative. Here, the benefit of guiding a major therapeutic decision is high and clearly outweighs the procedural risk. Biopsy is indicated.\n\n3.  **Phenotype Z**: Acute kidney injury with macroscopic hematuria or nephrotic-range proteinuria ($\\geq 3.5$ g/day). These are severe, high-risk presentations. Acute kidney injury in the context of IgA nephropathy could be due to crescentic disease, a nephrological emergency requiring aggressive immunosuppression. Nephrotic-range proteinuria also indicates severe disease and requires a definitive diagnosis to distinguish from other causes of nephrotic syndrome (like minimal change disease or membranous nephropathy) and to guide specific therapy. The pretest probability is very high ($0.85$). In these circumstances, the need for an urgent, accurate diagnosis to direct immediate, aggressive therapy is paramount. The benefit is extremely high, far outweighing the procedural risk. Biopsy is strongly indicated.\n\n**Synthesis of Biopsy Thresholds**\nBased on this analysis, a rational policy is to perform a biopsy in patients with features suggesting moderate-to-high risk of progression, where a definitive diagnosis will guide the use of specific, potent therapies like immunosuppression. These features include persistent proteinuria approaching or exceeding $1$ g/day, a documented decline in eGFR, or severe acute presentations. Conversely, in patients with low-risk features, where management would remain conservative regardless of the biopsy result, the procedure should be deferred to avoid unnecessary risk.\n\n**Evaluation of Options**\n\n*   **A. Perform biopsy in all suspected cases (any hematuria), because confirmatory histology always outweighs the small risk; do not consider proteinuria magnitude or eGFR trend.** This strategy is incorrect. It fails to perform a risk-benefit analysis, ignoring the fact that for low-risk patients (Phenotype X), the benefit of biopsy is negligible as it would not alter management, making the procedural risk unacceptable.\n\n*   **B. Recommend biopsy when proteinuria is persistent and $\\geq 1$ g/day and/or there is a sustained decline in eGFR of $> 10~\\text{mL/min/1.73~m}^2$ over $6$ months, or when macroscopic hematuria is accompanied by acute kidney injury; defer biopsy in isolated microscopic hematuria with proteinuria $< 0.5$ g/day and stable eGFR. This balances higher diagnostic yield in Phenotypes Y and Z against the $0.5$–$1.0\\%$ major complication risk, while avoiding low-yield biopsy in Phenotype X.** This option correctly identifies the key prognostic factors that create a high-benefit scenario for biopsy. The thresholds mentioned (proteinuria $\\geq 1$ g/day, declining eGFR, AKI) align perfectly with the characteristics of Phenotypes Y and Z, where biopsy is indicated. It also correctly identifies the low-risk profile of Phenotype X (low proteinuria, stable function) as a situation where biopsy should be deferred. The explicit justification provided in the option is a perfect summary of our risk-benefit analysis. This option is consistent with established clinical guidelines. **Correct**.\n\n*   **C. Only biopsy if nephrotic-range proteinuria $\\geq 3.5$ g/day or hypertension is present; do not biopsy for declining eGFR unless serum creatinine has doubled from baseline.** This option is incorrect because its thresholds are too restrictive. It would fail to identify patients in Phenotype Y with significant proteinuria ($>0.5$ g/day but less than nephrotic-range) and a declining eGFR who would benefit from early intervention. Waiting for serum creatinine to double from baseline represents an unacceptable delay, allowing for substantial and potentially irreversible loss of kidney function before a diagnosis is pursued.\n\n*   **D. Defer biopsy until eGFR has fallen below $60~\\text{mL/min/1.73~m}^2$ or serum creatinine has increased by $> 100\\%$, because risks otherwise outweigh benefits; isolated microscopic hematuria and subnephrotic proteinuria never warrant biopsy.** This option is also incorrect. It advocates for waiting too long, allowing significant kidney damage to occur before confirming a diagnosis. The purpose of biopsy is to guide therapy to *prevent* the eGFR from falling below $60~\\text{mL/min/1.73~m}^2$. It also incorrectly claims that subnephrotic proteinuria never warrants biopsy, which contradicts the rationale for biopsying patients like those in Phenotype Y who have progressive disease with proteinuria of $0.5-1.0$ g/day.\n\n*   **E. Biopsy whenever red blood cell (RBC) casts are detected on urinalysis, regardless of proteinuria or kidney function, because RBC casts make IgA nephropathy highly likely and justify the procedural risk.** This option is incorrect because it oversimplifies the decision-making process. While RBC casts confirm a glomerular source of hematuria, they are not, in isolation, a sufficient indicator of disease severity or risk of progression. A patient with RBC casts could still fit Phenotype X (low proteinuria, stable eGFR), where the risk-benefit analysis does not favor biopsy. The decision must be multifactorial, with proteinuria and eGFR trend being the most critical prognostic indicators for progression.", "answer": "$$\\boxed{B}$$", "id": "4389303"}, {"introduction": "A definitive diagnosis from a biopsy is not the end of the story; it is the beginning of risk stratification and treatment planning. This case study focuses on interpreting standardized histopathological findings using the Oxford MEST-C classification, a cornerstone of modern IgA nephropathy management. By integrating biopsy data with clinical parameters, you will practice formulating a comprehensive risk assessment and outlining an evidence-based therapeutic strategy for a patient. [@problem_id:5184330]", "problem": "A $12$-year-old boy presents with recurrent episodes of gross hematuria occurring within $24$ to $48$ hours of upper respiratory tract infections, new-onset periorbital edema, and blood pressure at the $95^{\\text{th}}$ percentile for age, sex, and height. Laboratory studies show serum creatinine of $0.7$ $\\text{mg/dL}$, estimated glomerular filtration rate of $>90$ $\\text{mL/min/1.73~m^2}$, urine protein-to-creatinine ratio of $1.5~\\text{g/g}$, and $24$-hour urine protein of $1.2$ $\\text{g/day}$. Urinalysis reveals dysmorphic red blood cells and red blood cell casts. Serologies are negative, and complement levels are normal. A kidney biopsy demonstrates dominant Immunoglobulin A (IgA) deposition in the mesangium by immunofluorescence. The Oxford classification reports: Mesangial hypercellularity (M1), Endocapillary hypercellularity (E0), Segmental glomerulosclerosis (S1), Tubular atrophy/interstitial fibrosis (T0), and Crescents (C0).\n\nUsing the Oxford MEST-C classification as the histopathologic framework and starting from core definitions of glomerular injury patterns, reason about the pathophysiology represented by each lesion class and synthesize a risk assessment for chronic kidney disease progression alongside the immediate therapeutic implications in a pediatric patient. Which of the following statements best reflects the expected risk and initial management strategy?\n\nA. High risk of rapid progression due to crescents; initiate pulse cyclophosphamide and systemic corticosteroids immediately.\n\nB. Moderate long-term progression risk driven by segmental sclerosis; prioritize optimized supportive therapy including Renin–Angiotensin–Aldosterone System blockade, blood pressure control, and proteinuria reduction, reserving immunosuppression unless proteinuria $\\ge 1$ $\\text{g/day}$ persists despite $3$ to $6$ months of supportive care.\n\nC. Low risk of progression because there are no adverse histologic markers; renin–angiotensin blockade is unnecessary even if proteinuria is $\\ge 1$ $\\text{g/day}$.\n\nD. Presence of endocapillary hypercellularity suggests steroid responsiveness; start corticosteroids now.\n\nE. Absence of tubular atrophy/interstitial fibrosis necessitates immunosuppression because inflammation is active and scarring is absent.", "solution": "The patient's presentation and diagnostic workup definitively establish a diagnosis of **Immunoglobulin A Nephropathy (IgAN)**. The task is to interpret the provided clinical and histopathologic data to assess risk and determine the appropriate initial management strategy.\n\n1.  **Analysis of Clinical Risk Factors**:\n    -   **eGFR**: $>90$ $\\text{mL/min/1.73~m^2}$. This indicates preserved kidney function, which is a favorable prognostic sign at presentation.\n    -   **Blood Pressure**: $95^{\\text{th}}$ percentile. This constitutes hypertension in pediatrics and is a significant risk factor for kidney disease progression. It requires treatment.\n    -   **Proteinuria**: $1.2$ $\\text{g/day}$ (or a UPCR of $1.5~\\text{g/g}$). Proteinuria of this magnitude ($>1$ $\\text{g/day}$) is a major independent risk factor for progressive loss of kidney function in IgAN.\n\n2.  **Analysis of Histopathologic Risk Factors (Oxford MEST-C Score)**:\n    -   **M1**: Mesangial hypercellularity. This indicates active inflammation in the mesangium.\n    -   **E0**: Absence of endocapillary hypercellularity. The presence of E lesions (E1) is associated with a more acute inflammatory presentation and may predict a better response to immunosuppressive therapy. Its absence (E0) in this case means this feature is not present.\n    -   **S1**: Presence of segmental glomerulosclerosis. S lesions represent scarring within a portion of the glomerulus. The presence of S1 is a strong and independent predictor of a worse long-term renal outcome, including a faster rate of eGFR decline. This is a significant adverse prognostic marker.\n    -   **T0**: Absence of tubular atrophy/interstitial fibrosis. T lesions represent chronic, often irreversible, damage to the tubulointerstitial compartment. The presence of T lesions (T1/T2) is one of the most powerful predictors of progression. The absence of T lesions (T0) is a favorable finding, suggesting that widespread chronic scarring has not yet occurred.\n    -   **C0**: Absence of crescents. C lesions (C1/C2) indicate severe, active glomerular injury. Their presence signifies a high risk of rapid progression. The absence of crescents (C0) is a very favorable finding, ruling out this aggressive disease course.\n\n3.  **Synthesis and Risk Assessment**:\n    The patient has a mixed prognostic profile.\n    -   **Favorable factors**: Preserved eGFR, T0, C0. These suggest the disease is not rapidly progressive and has not yet caused significant irreversible chronic damage.\n    -   **Adverse factors**: Hypertension, significant proteinuria ($>1$ $\\text{g/day}$), and the presence of segmental sclerosis (S1) on biopsy.\n    The combination, particularly the persistent high-grade proteinuria and the S1 lesion, places the patient at a **moderate to high long-term risk** for progression to chronic kidney disease (CKD), despite the currently normal eGFR.\n\n4.  **Management Strategy**:\n    The management of IgAN is guided by risk stratification, with the primary goals of reducing proteinuria and controlling blood pressure.\n    -   **Initial/Supportive Care**: According to KDIGO and other major guidelines, for any patient with IgAN and persistent proteinuria $>0.5$ $\\text{g/day}$, the first and most critical step is **optimized supportive care**. For this patient, who has proteinuria of $1.2$ $\\text{g/day}$ and hypertension, this includes:\n        -   **Renin–Angiotensin–Aldosterone System (RAAS) blockade**: Initiation of an Angiotensin-Converting Enzyme inhibitor (ACEi) or an Angiotensin II Receptor Blocker (ARB). This is the cornerstone of therapy to lower both systemic blood pressure and intraglomerular pressure, thereby reducing proteinuria.\n        -   **Blood Pressure Control**: Strict BP control, using RAAS blockade as the first-line agent.\n    -   **Immunosuppressive Therapy**: Immunosuppression (typically with corticosteroids) is generally reserved for patients who remain at high risk of progression despite a course of optimized supportive care. The current recommendation is to consider a $6$-month course of corticosteroids for patients who have persistent proteinuria $\\ge 1$ $\\text{g/day}$ despite at least $3-6$ months of maximized supportive care (including RAAS blockade) and have an eGFR $>50~\\text{mL/min/1.73~m}^2$. Immediate immunosuppression is reserved for severe presentations like crescentic disease, which this patient does not have (C0).\n\n**Option-by-Option Analysis**\n\n-   **A. High risk of rapid progression due to crescents; initiate pulse cyclophosphamide and systemic corticosteroids immediately.**\n    -   The biopsy explicitly states C0, meaning there are no crescents. Therefore, the risk of *rapid* progression is low, and the premise for this aggressive therapy is false.\n    -   **Verdict: Incorrect.**\n\n-   **B. Moderate long-term progression risk driven by segmental sclerosis; prioritize optimized supportive therapy including Renin–Angiotensin–Aldosterone System blockade, blood pressure control, and proteinuria reduction, reserving immunosuppression unless proteinuria $\\ge 1$ $\\text{g/day}$ persists despite $3$ to $6$ months of supportive care.**\n    -   This statement accurately reflects the patient's situation and the evidence-based management pathway. It correctly identifies the S1 lesion as a driver of long-term risk. It correctly prioritizes optimized supportive care (RAAS blockade, BP control) as the initial step. It correctly describes the indication for considering subsequent immunosuppression (persistent high-level proteinuria despite supportive care).\n    -   **Verdict: Correct.**\n\n-   **C. Low risk of progression because there are no adverse histologic markers; renin–angiotensin blockade is unnecessary even if proteinuria is $\\ge 1$ $\\text{g/day}$.**\n    -   This is factually incorrect. The S1 lesion is a well-established adverse histologic marker. Furthermore, withholding RAAS blockade in a patient with proteinuria of $1.2$ $\\text{g/day}$ is contrary to all established guidelines.\n    -   **Verdict: Incorrect.**\n\n-   **D. Presence of endocapillary hypercellularity suggests steroid responsiveness; start corticosteroids now.**\n    -   The biopsy explicitly states E0, indicating the *absence* of endocapillary hypercellularity. The premise of the statement is false.\n    -   **Verdict: Incorrect.**\n\n-   **E. Absence of tubular atrophy/interstitial fibrosis necessitates immunosuppression because inflammation is active and scarring is absent.**\n    -   The reasoning is flawed. The absence of chronic scarring (T0) represents a window of opportunity for intervention, but it does not, in itself, *necessitate* immunosuppression. The decision for immunosuppression is based on the failure to respond to optimized supportive care.\n    -   **Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "5184330"}]}